Zhejiang Yongtai Tech Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
3,437
- Stock Symbol
-
002326
- Investments
-
4
- Share Price
-
$1.96
- (As of Thursday Closing)
Zhejiang Yongtai Tech General Information
Description
Zhejiang Yongtai Technology Co Ltd is a fluorinated pharmaceutical, crop science, and new energy materials manufacturer with fluorine-containing technology as the core, technological innovation as the impetus, and intelligent manufacturing as the driving force, which is able to provide customized R&D services, manufacturing and technical services for domestic and overseas customers with its vertically integrated industrial chain, a flexible and comprehensive production platform, and specialized R&D innovation teams.
Contact Information
Website
www.yongtaitech.comCorporate Office
- Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone
- Taizhou, Zhejiang
- Taiwan
Corporate Office
- Zhejiang Provincial Chemical and Medical Raw Materials Base Linhai Zone
- Taizhou, Zhejiang
- Taiwan
Zhejiang Yongtai Tech Stock Performance
As of 19-Nov-2026, Zhejiang Yongtai Tech’s stock price is $1.96. Its current market cap is $1.82B with 925M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.96 | $1.98 | $1.94 - $4.39 | $1.82B | 925M | 18.6M | $0.06 |
Zhejiang Yongtai Tech Financials Summary
As of 30-Sep-2026, Zhejiang Yongtai Tech has a trailing 12-month revenue of $1.05B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,898,053 | 3,906,289 | 1,652,408 | 1,938,728 |
| Revenue | 1,053,240 | 724,983 | 639,596 | 583,479 |
| EBITDA | 97,393 | 82,367 | 12,843 | (40,388) |
| Net Income | 51,017 | (6,411) | (66,665) | (87,600) |
| Total Assets | 1,967,032 | 1,602,965 | 1,532,897 | 1,608,824 |
| Total Debt | 815,654 | 666,938 | 622,858 | 610,709 |
Zhejiang Yongtai Tech Patents
Zhejiang Yongtai Tech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026113514-A1 | Method for selectively and asymmetrically hydrogenating 4-substituted-1,2-dihydroquinoline and use thereof | Pending | 27-Nov-2024 | ||
| EP-4697432-A1 | Pre-embedding agent, pre-embedded lithium positive electrode, pre-embedded sodium positive electrode, secondary battery comprising same, method for pre-embedding lithium, and method for pre-embedding sodium | Pending | 14-Apr-2023 | ||
| EP-4697432-A4 | Pre-embedding agent, pre-embedded lithium positive electrode, pre-embedded sodium positive electrode, secondary battery comprising same, method for pre-embedding lithium, and method for pre-embedding sodium | Pending | 14-Apr-2023 | ||
| US-20250313814-A1 | Omega-transaminase mutant and application thereof | Pending | 16-Dec-2022 | ||
| EP-4506451-A1 | Omega-transaminase mutant and use thereof | Pending | 16-Dec-2022 | C12N9/1096 |
Zhejiang Yongtai Tech Signals
Zhejiang Yongtai Tech Investments & Acquisitions (4)
Zhejiang Yongtai Tech’s most recent deal was a Early Stage VC with Carelinker. The deal was made on 06-Jul-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carelinker | 06-Jul-2018 | Early Stage VC | Enterprise Systems (Healthcare) | ||
| Foshan Chiral Pharmaceutical | 08-Apr-2016 | Merger/Acquisition | Pharmaceuticals | ||
| Zhejiang Chiral Medicine Chemicals | 08-Apr-2016 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Carelinker | 30-Mar-2016 | Early Stage VC | Enterprise Systems (Healthcare) |
Zhejiang Yongtai Tech ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.49 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Chemicals
Industry
of 503
Rank
Percentile
Commodity Chemicals
Subindustry
of 208
Rank
Percentile
Zhejiang Yongtai Tech Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zhejiang Chiral Medicine Chemicals | Hangzhou, China | 1998 | |
| Foshan Chiral Pharmaceutical | Foshan, China | 1959 |
Zhejiang Yongtai Tech FAQs
-
When was Zhejiang Yongtai Tech founded?
Zhejiang Yongtai Tech was founded in 1999.
-
Where is Zhejiang Yongtai Tech headquartered?
Zhejiang Yongtai Tech is headquartered in Taizhou, Taiwan.
-
What is the size of Zhejiang Yongtai Tech?
Zhejiang Yongtai Tech has 3,437 total employees.
-
What industry is Zhejiang Yongtai Tech in?
Zhejiang Yongtai Tech’s primary industry is Other Chemicals and Gases.
-
Is Zhejiang Yongtai Tech a private or public company?
Zhejiang Yongtai Tech is a Public company.
-
What is Zhejiang Yongtai Tech’s stock symbol?
The ticker symbol for Zhejiang Yongtai Tech is 002326.
-
What is the current stock price of Zhejiang Yongtai Tech?
As of 19-Nov-2026 the stock price of Zhejiang Yongtai Tech is $1.96.
-
What is the current market cap of Zhejiang Yongtai Tech?
The current market capitalization of Zhejiang Yongtai Tech is $1.82B.
-
What is Zhejiang Yongtai Tech’s current revenue?
The trailing twelve month revenue for Zhejiang Yongtai Tech is $1.05B.
-
What is Zhejiang Yongtai Tech’s annual earnings per share (EPS)?
Zhejiang Yongtai Tech’s EPS for 12 months was $0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process